Sudarshan Pharma Industries
25.15
-0.05(-0.20%)
Market Cap₹605.30 Cr
PE Ratio33.60
IndustryChemicals
Company Performance:
1D-0.20%
1M+4.84%
6M-10.59%
1Y-39.40%
5Y+262.39%
View Company Insightsright
More news about Sudarshan Pharma Industries
08Sept 25
Sudarshan Pharma Secures Approval for Project Relocation and Boosts Manufacturing Capacity
Sudarshan Pharma Industries Limited (SPIL) has received approval to relocate its Vitamin B6 and B1 projects from Maharashtra to Gujarat, with an extended production timeline to December 31, 2027. Additionally, SPIL has invested Rs. 25.50 crore in acquiring a fully operational API manufacturing facility in Telangana from Srigen Lifesciences Private Limited. This strategic move is expected to enhance production capacity, expand product portfolio, and accelerate market responsiveness.
08Sept 25
Sudarshan Pharma Boosts Manufacturing Capacity with ₹25.5 Crore API Facility Acquisition
Sudarshan Pharma Industries Limited (SPIL) has acquired an operational Active Pharmaceutical Ingredient (API) facility in Telangana for ₹25.5 crore from Srigen Lifesciences Private Limited. The acquisition includes land, buildings, and plant & machinery. The facility can produce complex, high-margin molecules like Ropivacaine, Bupivacaine, and Sitagliptin. This move is expected to enhance SPIL's manufacturing capacity, expand its product portfolio, and accelerate growth in the API and specialty chemicals sectors. The acquisition offers immediate manufacturing scale-up, faster time-to-market, and regulatory advantages.
18Aug 25
Sudarshan Pharma Industries CFO Manoj Lodha Resigns for Strategic Role
Sudarshan Pharma Industries announced the resignation of CFO Manoj Lodha, effective August 5, 2025. Lodha is leaving to pursue a higher strategic role in a different industry. The company confirmed Lodha is not related to any directors and will initiate the process of identifying a new CFO for a smooth transition.
18Aug 25
Sudarshan Pharma Industries Posts Impressive Q1 Turnaround with ₹37 Crore Net Profit
Sudarshan Pharma Industries has reported a significant turnaround in Q1 financial performance. The company's net profit reached ₹37.00 crore, compared to a loss of ₹12.00 crore in the same quarter last year. Revenue grew by 40% to ₹140.00 crore from ₹100.00 crore year-over-year. EBITDA surged to ₹10.30 crore from ₹2.00 crore, with the EBITDA margin expanding to 7.22% from 1.94%. This strong performance across all key metrics indicates successful implementation of growth and profitability strategies.
05Aug 25
Sudarshan Pharma Acquires Dubai-Based Cibachem, Expands Middle East Presence; CFO Resigns
Sudarshan Pharma Industries Limited has acquired Cibachem General Trading LLC, a Dubai-based company, as a wholly-owned subsidiary for Rs. 55.00 lakh. The acquisition involves 300 shares representing 100% of Cibachem's paid-up share capital. Cibachem, established in 2013, operates in general trading. Separately, Sudarshan Pharma's CFO, Mr. Manoj Lodha, has resigned effective August 5, 2025. The acquisition aims to expand Sudarshan Pharma's customer base in the Middle East region.
05Aug 25
Sudarshan Pharma Expands Middle East Presence with 100% Acquisition of Dubai-Based Cibachem General Trading
Sudarshan Pharma Industries Limited has acquired a 100% stake in Cibachem General Trading LLC, a Dubai-based company, for Rs. 55.00 lakh. The acquisition involves 300 equity shares of Cibachem, each with a face value of AED 1,000. Cibachem, established in 2013, focuses on general trading activities. This move aligns with Sudarshan Pharma's strategy to expand its presence in the Middle East market. The company also announced the resignation of Mr. Manoj Lodha as CFO, effective August 5, 2025.
20Jun 25
Sudarshan Pharma Approves ₹1,500 Crore Fundraising, Plans US Subsidiary
Sudarshan Pharma Industries Limited's board has approved a fundraising plan of up to ₹1,500 crore. The company also plans to establish a wholly-owned subsidiary, Sudarshan Industries LLC, in the United States. The new subsidiary will focus on manufacturing chemical products, producing pharmaceutical items, and trading in FMCG products. This move aims to expand the company's global presence and diversify its product portfolio.
13May 25
Sudarshan Pharma Industries Set to Acquire Cibachem Shares for ₹5.5 Crore
Sudarshan Pharma Industries has announced the acquisition of 300 shares of Cibachem for ₹5.5 crore. This strategic move aims to expand Sudarshan Pharma's portfolio and potentially strengthen its position in the pharmaceutical sector. The acquisition could indicate the company's intentions to diversify operations or enhance its existing product line.
04May 25
Sudarshan Pharma Industries Reports Robust H2 FY25 Results with 43% Profit Surge
Sudarshan Pharma Industries announced impressive financial results for H2 FY25, with net sales up 19% to ₹277.00 crore and net profit surging 43% to ₹7.00 crore year-over-year. For the full FY25, net sales increased 9% to ₹505.00 crore, while net profit grew 45% to ₹16.00 crore. The company's performance is attributed to its focus on expanding exports, boosting domestic sales of manufactured medicines, and enhancing profit margins from API reselling.
25Apr 25
Sudarshan Pharma Industries Reports 52% Surge in Q4 Profit, Robust Annual Performance
Sudarshan Pharma Industries Ltd reported a 52% increase in Q4 profit to ₹10.03 crore, with revenue rising 16.6% to ₹277.26 crore. For FY2025, total income reached ₹507.57 crore, up from ₹466.15 crore in FY2024. Net profit for the year increased to ₹15.96 crore from ₹11.46 crore. The company's EPS improved to ₹0.66, and its financial position strengthened with total assets at ₹402.41 crore. The debt-to-equity ratio stood at 1.30, and the interest coverage ratio improved to 2.65.
20Feb 25
Sudarshan Pharma Industries Completes Polish Subsidiary Incorporation
Sudarshan Pharma Industries Limited has successfully incorporated its wholly-owned subsidiary in Poland with an investment of PLN 5,000 (₹1,30,000). The new entity, located in Warsaw, will focus on manufacturing chemicals, fertilizers, pharmaceuticals, and wholesale operations, enabling the company to expand its customer base in the European region.
1 Year Returns:-39.40%
Industry Peers
Kiri Industries
588.55
(-0.01%)
Indokem
695.85
(-3.26%)
Heubach Colorants
458.55
(-2.56%)
Bhageria Industries
185.94
(-1.26%)
Bodal Chemicals
53.39
(+0.02%)
Vipul Organics
217.50
(-1.49%)